Robert Kaner, MD
Associate Professor of Clinical Medicine and Genetic Medicine
Weill Cornell Medical College, New York, NY
- Be able to describe the lung manifestations of HIV, including opportunistic infections, conventional pneumonias, lung cancers, pulmonary hypertension and COPD.
- Know how the effects of HIV on the lung have changed from the pre-HAART era to the present.
- Understand the diagnostic criteria for COPD and emphysema.
This CME activity was approved for AMA PRA Category 1 Credit™ on September 16, 2014 and will terminate September, 2017.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
- After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
- You must achieve at least 70% correct to receive your CME certificate.
- If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
- Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
- Dr. Kaner (Presenter) had the following personal financial relationships in the prior 12 months with manufacturers of the products or services that may be presented in this CME activity: Principal Investigator in IPF clinical study at Bristol-Myers Squibb; Member, RAINIER Endpoints Adjudication Committee (IPF) at Gilead Sciences; Data Monitoring Committee for Asthma and COPD clinical trials at Janssen Pharmaceuticals; Speakers Bureau for Asthma at Merck & Co. Dr. Kaner supported his presentation and clinical recommendations with the best available evidence from the medical literature, and submitted his slides in advance for adequate peer review.
This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.